2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 117

Using Goutpro to Make Medical Trainees Gout Pros- a Single Blinded Randomized Control Study
Abstract Number: 2975

Using Immune and Metabolic Phenotyping to Understand the Immunopathogenesis of Juvenile-Onset SLE and Stratify Patient Groups
Abstract Number: 1255

Using PROs to Guide Patient-Centered Conversations and Care in Inflammatory Arthritis: The Clinician Perspective
Abstract Number: 2255

Using PROs to Guide Patient-Centered Conversations and Care in Inflammatory Arthritis: The Patient Perspective
Abstract Number: 1986

Using the BILAG to Assess the Activity of Lupus in Patients with Fibromyalgia
Abstract Number: 881

Ustekinumab Is Superior to TNF Inhibitor Treatment in Resolving Enthesitis in Psa Patients with Active Enthesitis- Results from the Enthesial Clearance in Psoriatic Arthritis Study
Abstract Number: 104

Utility of a Virtual Rheumatology Clinic for Community Based Internal Medicine Residency Program
Abstract Number: 2090

Utility of Anakinra in Acute Crystalline Diseases: A Retrospective Study Comparing a University Hospital with Veterans Affairs Medical Center
Abstract Number: 869

Utility of Carotid Ultrasound Compared to Framingham Risk Score in Predicting Cardiovascular Mortality in Rheumatoid Arthritis
Abstract Number: 1172

Utility of Interstitial Pneumonia with Autoimmune Features (IPAF) Proposed Criteria in the Classification of Patients with CTD-Associated Interstitial Lung Disease in a Single Centre
Abstract Number: 2630

Utility of the Korean Version of Systemic Lupus Activity Questionnaire, in Clinical Practice: Its Correlation with Disease Activity Indices of Systemic Lupus Erythematosus
Abstract Number: 2531

Utilization of the Psoriasis Epidemiology Screening Tool to Identify Signs and Symptoms of Early Psoriatic Arthritis Among Those with Psoriasis: Analysis from the Corrona Psoriasis Registry
Abstract Number: 1858

Utilizing Needs Assessment Data to Establish Foundational Training for Adult and Pediatric Nurse Practitioners (NP) and Physician Assistants (PA) Entering Rheumatology Practice
Abstract Number: 2294

Utilizing the Pediatric Rheumatology Care and Outcomes Improvement Network to Assess Practice Pattern Variation in Juvenile Idiopathic Arthritis
Abstract Number: 1852

Validating Patient Reported Outcomes in Older Veterans with Chronic Back Pain

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].